PET/CT

Positron emission tomography/computed tomography is a hybrid nuclear medicine imaging technique that helps radiologists spot abnormal metabolic activity. PET/CT is commonly used to diagnose cancers, heart diseases and certain brain disorders, among other conditions.

Software glitch prompts FDA recall of popular PET systems
The recall was issued due to the potential for the systems to produce artifacts during PET exams.
Bayer expands into molecular imaging with cardiac amyloidosis tracer acquisitions
Bayer is acquiring two cardiac amyloidosis radiotracers from Attralus, one for PET and one for SPECT. The SPECT tracer is also a theranostic agent to both image and treat amyloidosis.
Key trends in medical imaging systems at RSNA 2025
Sarah-Jane James, imaging market analyst for Signify Research, discusses key trends in the specialty that she saw at the Radiological Society of North America's annual meeting.
Positron raises $2M to expand PET-CT commercialization
The New York-based imaging company is now focused on expanding sales for the cost-effective PET-CT system it developed with Neusoft Medical Systems.
Leading nuclear medicine organizations collaborate to streamline PET accreditation
The groups have jointly endorsed a unified framework “to standardize and harmonize quantitative PET imaging worldwide.”

Novel radiotracer could improve the diagnosis of interstitial lung disease

Researchers are hopeful that uptake of the molecular SPECT imaging agent will help providers more ably monitor disease progression.

New PET technique improves imaging of pediatric neuroblastoma.

New PET technique slashes scan times, improves image quality in neuroblastoma cases

The method also reduces radiation doses and eliminates the need for sedation or general anesthesia.

'Game changer' prostate imaging agent granted FDA's Fast Track designation

The PET agent was developed for men with PSMA-positive lesions who have suspected metastasis and are candidates for initial definitive therapy.

FAPI PET improves staging and clinical management for a significant portion of pancreatic cancers

Fibroblast activation protein inhibitor PET imaging may provide more accurate insight into the spread of pancreatic cancer than more commonly used 18F-FDG PET/CT.

Hall of Fame Health partnership set to advance study of neurodegeneration via new PET imaging agent

The organization is teaming up with CereMark Pharma to conduct research on improving outcomes in soldiers and athletes with neurodegenerative conditions.

Reducing prostate cancer treatment dosage alleviates downsides while remaining effective

Reducing certain treatments by around 25% and 50% still achieves promising PSA response rates, but reduces some of the unwanted side effects of therapy, like dry mouth.

COVID remnants still show up on PET/CT scans years after infection

That’s according to new PET imaging that shows the presence of activated T cells in the brain, spinal cord, gut and lung tissues of individuals who have recovered from COVID.

Frequent sleep disruptions may increase amyloid deposits down the road

Daily sleep disruptions could increase the risk of developing Alzheimer’s disease in the future, new research suggests.

PET/CT

Software glitch prompts FDA recall of popular PET systems

Bayer expands into molecular imaging with cardiac amyloidosis tracer acquisitions

Key trends in medical imaging systems at RSNA 2025

Positron raises $2M to expand PET-CT commercialization

Leading nuclear medicine organizations collaborate to streamline PET accreditation